U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27
You may also be interested in...
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing
PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing
PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur, Cardio Drug, During R&D Update
Research suggests periodontal disease leads to systemic threats, including cardiovascular disease, oropharyngeal and pancreatic cancers and diabetes, expert says.